Written answers

Tuesday, 9 December 2008

Department of Health and Children

Medicinal Products

10:00 pm

Photo of James ReillyJames Reilly (Dublin North, Fine Gael)
Link to this: Individually | In context

Question 202: To ask the Minister for Health and Children the reason wholesale cost of medicines here are higher than the over the counter or retail cost of medicines in Spain; her proposals to obtain a better and more realistic price for such medicines here from manufacturers in particular; and if she will make a statement on the matter. [44723/08]

Photo of Mary HarneyMary Harney (Dublin Mid West, Progressive Democrats)
Link to this: Individually | In context

EU member states are the main purchasers of medicines in their domestic markets. They naturally seek to control drug prices, but the extent of this control varies widely. Some countries, such as the UK and Germany, rely more on market forces to set prices. Spain and Portugal, on the other hand, closely regulate and control prices. Ireland's pricing policy is somewhere in the middle of the European league as, with its relatively small market, it must seek to balance value for money in State drug spending with reliability and continuity of supply for essential products.

Price comparison in different markets is difficult. Patent protection in Ireland allows originator companies exclusive rights to the market for ten years for new medicines. In Spain, for example, until 1992 there was no intellectual property protection for medicines and no patent protection for new products. This kept prices down, but may change with patent and intellectual property exclusivity. In addition, some products that are prescription-only in Ireland are available without prescription in some other states.

My Department and the Health Service Executive concluded negotiations in 2006 with pharmaceutical manufacturers on important new agreements setting out the pricing and supply of medicines for the Irish health service.

These agreements provide increased value for money for the State and the consumer through a reduction in the price of existing drugs and medicines coming off patent and through the use of a new mechanism for pricing new drugs. Over the period of the agreements, which run to 2010, it is expected to achieve savings of the order of €260 million across the GMS and community drugs schemes, and in the cost of drugs to hospitals, through off-patent price cuts of 35% for drugs with substitutable alternatives. In addition to the savings quantified, there will be further savings as generic manufacturers respond to the lower price of branded drugs.

There will also be savings through the new pricing mechanism for new medicines, along with two price reviews for new medicines over the term of the agreements. Finally, for the first time, reimbursement of new drugs in Ireland can now be informed by pharmacoeconomic assessment, in line with other EU countries.

I must stress that no single measure will contain the rate of increase in expenditure on medicines and drugs. Indeed, international experience has shown that this is a very difficult task, as the sophistication and range of treatments continue to increase along with increased expectations on the part of patients.

Comments

No comments

Log in or join to post a public comment.